R&D
Paper on a new in vivo genome editing technology using CRISPR-Cas3 published in Nature Biotechnology
Through joint research between C4U Corporation and a research team led by Professor Tomoji Mashimo of the Division of Animal Genetics, Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo (IMSUT), a new method for the in vivo application of CRISPR-Cas3 technology has been established. The research results were published in the online edition of the British scientific journal Nature Biotechnology on January 5, 2026.
For further details, please refer to the press release from the Institute of Medical Science, the University of Tokyo, “New Study Explores Therapeutic Potential of CRISPR-Cas3 Genome-Editing System”.
<Reference>
Journal: Nature Biotechnology
Title of original paper: CRISPR–Cas3-based editing for targeted deletions in a mouse model of transthyretin amyloidosis
DOI: 10.1038/s41587-025-02949-6